12.77

3.04% -0.40

Trevi Therapeutics Inc (TRVI)

Overview News Price History Option Chain Financials Discussions Forecast

Trevi Therapeutics Inc stock is traded at $12.77, with a volume of 1.84M. It is down -3.04% in the last 24 hours and up +7.76% over the past month. Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.

Previous Close:

$13.17

Open:

$13.12

24h Volume:

1.84M

Relative Volume:

0.90

Market Cap:

$1.64B

Revenue:

Net Income/Loss:

$-29.07M

P/E Ratio:

-44.03

EPS:

-0.29

Net Cash Flow:

$-31.85M

1W Performance:

-5.20%

1M Performance:

+7.76%

6M Performance:

+106.97%

1Y Performance:

+254.72%

1-Day Range:

$12.71

$13.45

1-Week Range:

$12.71

$14.39

52-Week Range:

$3.4715

$14.39

Trevi Therapeutics Inc Stock (TRVI) Company Profile

Name

Trevi Therapeutics Inc

Sector

Healthcare (1123)

Industry

Biotechnology (627)

Phone

203-304-2499

Address

195 CHURCH STREET, NEW HAVEN, CT

Employee

Twitter

@TreviThera

Next Earnings Date

2025-03-18

Latest SEC Filings

TRVI's Discussions on Twitter

Compare TRVI with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TRVI Trevi Therapeutics Inc	12.77	1.69B	0	-29.07M	-31.85M	-0.29
VRTX Vertex Pharmaceuticals Inc	452.04	113.14B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	741.29	78.49B	14.25B	4.58B	3.88B	41.77
ARGX Argen X Se Adr	877.94	54.76B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	397.55	54.51B	3.21B	43.57M	221.36M	0.2405
INSM Insmed Inc	197.01	41.64B	447.02M	-1.18B	-906.14M	-6.1812

Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-13-25	Initiated	Leerink Partners	Outperform
Aug-21-25	Initiated	Morgan Stanley	Overweight
Jul-01-25	Initiated	Cantor Fitzgerald	Overweight
May-28-25	Initiated	H.C. Wainwright	Buy
Mar-10-25	Reiterated	Needham	Buy
Mar-10-25	Upgrade	Raymond James	Outperform → Strong Buy
Dec-12-24	Reiterated	H.C. Wainwright	Buy
Sep-09-24	Resumed	Leerink Partners	Outperform
Aug-30-24	Initiated	H.C. Wainwright	Buy
Aug-30-24	Initiated	Raymond James	Outperform
Jun-13-24	Initiated	Rodman & Renshaw	Buy
Apr-12-23	Initiated	B. Riley Securities	Buy
Nov-22-22	Initiated	SVB Leerink	Outperform
Jun-03-19	Initiated	BMO Capital Markets	Outperform
Jun-03-19	Initiated	Needham	Buy
Jun-03-19	Initiated	SVB Leerink	Outperform
Jun-03-19	Initiated	Stifel	Buy

View All

Trevi Therapeutics Inc Stock (TRVI) Latest News

Dec 11, 2025

Trevi Therapeutics stock hits all-time high of 14.01 USD By Investing.com - Investing.com Nigeria

Dec 11, 2025

Marshall Wace LLP Has $13.55 Million Stock Position in Trevi Therapeutics, Inc. $TRVI - MarketBeat

Dec 11, 2025

Trevi Therapeutics Stock Surges to Record High on Clinical and Strategic Momentum - AD HOC NEWS

Dec 11, 2025

Trevi Therapeutics (NASDAQ:TRVI) Hits New 12-Month HighTime to Buy? - MarketBeat

Dec 11, 2025

Dec 10, 2025

226,381 Shares in Trevi Therapeutics, Inc. $TRVI Bought by Prudential Financial Inc. - MarketBeat

Dec 07, 2025

Dec 06, 2025

Trevi Therapeutics Appoints New Chief Financial Officer - The Globe and Mail

Dec 06, 2025

Affinity Asset Advisors LLC Raises Holdings in Trevi Therapeutics, Inc. $TRVI - MarketBeat

Dec 06, 2025

Dec 05, 2025

Trevi Therapeutics appoints David Hastings as chief financial officer By Investing.com - Investing.com Nigeria

Dec 05, 2025

Trevi Therapeutics, Inc. Announces Appointment of David Hastings as Chief Financial Officer, Effective January 6, 2026 - marketscreener.com

Dec 05, 2025

Trevi Therapeutics, Inc. Announces the Hiring of David Hastings to Serve as the Company?s Principal Financial Officer, Effective January 6, 2026 - marketscreener.com

Dec 05, 2025

New Haven biotech names new CFO - Hartford Business Journal

Dec 05, 2025

Trevi Therapeutics appoints David Hastings as chief financial officer - Investing.com

Dec 05, 2025